Exelixis has signed an exclusive collaboration and license agreement with STORM Therapeutics to discover and develop inhibitors of novel RNA modifying enzymes. Initially, the companies will focus on
Intellia Therapeutics, and SparingVision have entered into a strategic collaboration to develop new genomic medicines making use of CRISPR/Cas9 technology to treat ocular diseases. A clinical-stage genome editing
The US Food and Drug Administration (FDA) has approved biologics license application (sBLA) and the European Medicines Agency (EMA) has validated the type-II variation application for Novartis’ Beovu
Poseida Therapeutics has signed a research collaboration and license agreement with Takeda Pharmaceutical Company to develop up to eight in vivo gene therapy programmes. They will focus on
Pacira BioSciences has signed a definitive agreement to acquire biopharmaceutical firm Flexion Therapeutics to strengthen its position in non-opioid pain management. Founded in 2007, Flexion is focused on
Brii Biosciences has filed an emergency use authorization (EUA) application for its investigational SARS-CoV-2 monoclonal antibody combination therapy, BRII-196/BRII-198, to the US Food and Drug Administration (FDA). Obtained
As per the deal, Samsung Biologics will offer end-to-end CDMO services including cell line development, clinical drug substance and drug product production services. Samsung Biologics’ development and production
The acquisition is in accordance with the development, option and stock purchase agreement (DOSPA) entered by Fortress Biotech, Caelum, Alexion and others. Biopharmaceutical company Fortress founded Caelum, which
AZD7442 is a cocktail of two long-acting antibodies — tixagevimab (AZD8895) and cilgavimab (AZD1061). The US Vanderbilt University Medical Center-discovered LAAB combination was licenced to AstraZeneca in June last year.
An experimental product candidate, ACER-001 is being developed to treat several inborn errors of metabolism, such as UCDs and maple syrup urine disease (MSUD). The application to the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.